

Low-Dose Methotrexate for the Prevention of Atherosclerosis

New England Journal of Medicine

380, 752-762

DOI: [10.1056/nejmoa1809798](https://doi.org/10.1056/nejmoa1809798)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Strategies to Overcome Residual Risk During Statins Era. <i>Circulation Journal</i> , 2019, 83, 1973-1979.	0.7	27
2	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 56.	18.1	1,601
3	Imaging residual inflammatory cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 748-758.	1.0	86
4	New Promises and Challenges on Inflammation and Atherosclerosis: Insights From CANTOS and CIRT Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 90.	1.1	8
5	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 461-474.	3.5	95
6	Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-32.	1.9	369
7	Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. <i>Endocrine Reviews</i> , 2019, 40, 1080-1091.	8.9	70
8	Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1510-1519.	1.1	57
9	Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions. <i>International Journal of Cardiology</i> , 2019, 293, 238-247.	0.8	12
10	Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-26.	1.9	388
11	Inflammation as a Therapeutic Target in Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1109.	1.0	118
12	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 38.	0.4	1
13	Heterogeneity of Macrophages in Atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1237-1246.	1.8	9
14	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. <i>Blood Reviews</i> , 2019, 37, 100587.	2.8	23
15	The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. <i>American Heart Journal</i> , 2019, 215, 62-69.	1.2	99
16	Lumpers and splitters: the bumpy road to precision medicine. <i>European Heart Journal</i> , 2019, 40, 3292-3296.	1.0	15
17	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	1.2	39
18	Pharmacokinetics and Novel Metabolite Identification of Tartary Buckwheat Extracts in Beagle Dogs Following Co-Administration with Ethanol. <i>Pharmaceutics</i> , 2019, 11, 525.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. <i>BMC Medicine</i> , 2019, 17, 197.	2.3	35
20	Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial. <i>Complementary Therapies in Medicine</i> , 2019, 47, 102209.	1.3	8
21	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1198-1208.	2.3	18
22	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 861-870.	1.4	14
23	Immunity, Inflammation and Heart Failure: Their Role on Cardiac Function and Iron Status. <i>Frontiers in Immunology</i> , 2019, 10, 2315.	2.2	19
24	Immunobiology of Atherosclerosis: A Complex Net of Interactions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5293.	1.8	79
25	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102401.	2.5	7
26	IL-1 β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1764.	1.0	21
27	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e1-e9.	1.1	45
28	Inflammation in atherosclerotic cardiovascular disease. <i>F1000Research</i> , 2019, 8, 1402.	0.8	37
29	Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. <i>Rheumatology</i> , 2019, 58, 1900-1906.	0.9	62
30	Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques. <i>Molecules</i> , 2019, 24, 3072.	1.7	29
31	Sex Differences in the Association between Inflammation and Ischemic Heart Disease. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1471-1480.	1.8	22
32	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. <i>European Heart Journal</i> , 2019, 40, 3901-3909.	1.0	54
33	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke. <i>Circulation Research</i> , 2019, 125, 773-782.	2.0	78
34	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
35	The IL-1 family of cytokines and receptors in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2019, 15, 612-632.	3.5	247
36	The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. <i>European Cardiology Review</i> , 2019, 14, 50-59.	0.7	692

#	ARTICLE	IF	CITATIONS
37	Cardiac imaging and circulating biomarkers for primary prevention in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2019, 4, 299-308.	0.4	0
38	C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort. American Heart Journal, 2019, 217, 94-100.	1.2	13
39	From Focal Lipid Storage to Systemic Inflammation. Journal of the American College of Cardiology, 2019, 74, 1594-1607.	1.2	158
40	A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. Npj Genomic Medicine, 2019, 4, 23.	1.7	91
41	NLRP1 inhibiting pathway to be explored in anti-atherosclerosis treatment approach. International Journal of Cardiology, 2019, 278, 265.	0.8	1
42	Anticytokine Agents. Circulation Research, 2019, 124, 437-450.	2.0	188
43	PCSK9 inhibition 2018: riding a new wave of coronary prevention. Clinical Science, 2019, 133, 205-224.	1.8	8
44	<p>Obesity paradox in cardiovascular disease: where do we stand?</p>. Vascular Health and Risk Management, 2019, Volume 15, 89-100.	1.0	234
45	Ischaemic heart disease, infection, and treatment of infection. European Heart Journal, 2019, 40, 3846-3847.	1.0	2
46	Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 1385-1392.	1.8	58
47	The role of sodium in modulating immune cell function. Nature Reviews Nephrology, 2019, 15, 546-558.	4.1	74
48	ST-segment elevation myocardial infarction. Nature Reviews Disease Primers, 2019, 5, 39.	18.1	179
49	Immune Responses in Context. Circulation, 2019, 139, 2567-2569.	1.6	1
50	hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcareâ€Based Study. Journal of the American Heart Association, 2019, 8, e012638.	1.6	79
51	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e98-e124.	1.6	376
52	Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms. Revista Espanola De Cardiologia (English Ed), 2019, 72, 767-773.	0.4	9
53	From the last EuroPrevent towards the first ESC Preventive Cardiology Congress. European Journal of Preventive Cardiology, 2019, 26, 1408-1411.	0.8	0
54	Methotrexate for Prevention of Cardiovascular Events. New England Journal of Medicine, 2019, 380, 2276-2277.	13.9	2

#	ARTICLE	IF	CITATIONS
55	Targeting interleukin-1: implications for long-term cardiovascular management following radiotherapy. <i>European Heart Journal</i> , 2019, 40, 2504-2506.	1.0	1
56	Immunotherapy for cardiovascular disease. <i>European Heart Journal</i> , 2019, 40, 3937-3946.	1.0	127
57	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2019, 36, 1549-1573.	1.3	3
58	Cardiovascular disease in kidney transplant recipients: leave no stone unturned. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 727-730.	0.4	2
59	Adaptive immune cells in calcific aortic valve disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H141-H155.	1.5	47
60	The Role of Inflammation in HIV-Associated Atherosclerosis—One Size May Not Fit All. <i>Journal of Infectious Diseases</i> , 2019, 221, 495-497.	1.9	6
61	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2401-2409.	1.2	69
62	Immunometabolism orchestrates training of innate immunity in atherosclerosis. <i>Cardiovascular Research</i> , 2019, 115, 1416-1424.	1.8	44
63	Evaluation and Management of the Vulnerable Plaque. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	3
64	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	1.0	54
65	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 52-62.	2.2	10
66	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	2.2	31
67	Immunometabolism of Phagocytes and Relationships to Cardiac Repair. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 42.	1.1	30
68	Immune mechanisms of hypertension. <i>Nature Reviews Immunology</i> , 2019, 19, 517-532.	10.6	281
69	Cytokine Circuits in Cardiovascular Disease. <i>Immunity</i> , 2019, 50, 941-954.	6.6	125
70	Treatment of atherosclerotic plaque: perspectives on theranostics. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 1029-1043.	1.2	56
71	Immunoprofiling comes of age. <i>Nature Medicine</i> , 2019, 25, 362-364.	15.2	3
73	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 16.	1.1	109

#	ARTICLE	IF	CITATIONS
74	Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 4-15.	0.9	5
75	Novel findings in neutrophil biology and their impact on cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, 1266-1285.	1.8	118
76	Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H1354-H1365.	1.5	8
77	When, where, and how to target vascular inflammation in the post-CANTOS era?. <i>European Heart Journal</i> , 2019, 40, 2492-2494.	1.0	13
78	NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1599.	1.8	138
79	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. <i>Drugs and Aging</i> , 2019, 36, 493-510.	1.3	16
80	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 791-803.	0.9	37
81	Markers or Makers. <i>Hypertension</i> , 2019, 73, 767-769.	1.3	12
82	Diabetes Mellitus and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 558-568.	1.1	98
83	How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 107-111.	1.0	19
84	Highlights of AHA Scientific Sessions 2018: a report from the Scientists of Tomorrow. <i>Cardiovascular Research</i> , 2019, , .	1.8	1
85	Stable Ischemic Heart Disease. <i>Annals of Internal Medicine</i> , 2019, 171, ITC17.	2.0	18
86	Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future. <i>Chinese Medical Journal</i> , 2019, 132, 2972-2983.	0.9	8
87	Inflammation as a Treatment Target after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2562-2563.	13.9	34
88	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	13.9	1,696
89	Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. <i>PLoS ONE</i> , 2019, 14, e0227142.	1.1	7
90	New evidence on the role of inflammation in CVD risk. <i>Current Opinion in Cardiology</i> , 2019, 34, 418-423.	0.8	26
91	Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 297-305.	0.8	23

#	ARTICLE	IF	CITATIONS
92	Single-cell immune landscape of human atherosclerotic plaques. <i>Nature Medicine</i> , 2019, 25, 1576-1588.	15.2	540
93	Role of serum amyloid A in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2019, 30, 320-325.	1.2	43
96	Targeting inflammation in CVD: advances and challenges. <i>Nature Reviews Cardiology</i> , 2019, 16, 74-75.	6.1	29
97	Colchicine in Cardiovascular Disease: Repurposing an Ancient Gout Drug. <i>Clinical Therapeutics</i> , 2019, 41, 8-10.	1.1	16
98	Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. <i>Clinical Therapeutics</i> , 2019, 41, 41-48.	1.1	65
99	Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the <scp>CANTOS</scp> and <scp>CIRT</scp> clinical trials. <i>Journal of Internal Medicine</i> , 2019, 285, 503-509.	2.7	32
100	Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 128.	3.0	61
101	Immunity and Inflammation in Atherosclerosis. <i>Circulation Research</i> , 2019, 124, 315-327.	2.0	972
102	Targeting inflammation to reduce ASCVD in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 1-3.	1.2	11
103	No benefit of methotrexate on the risk of cardiovascular events. <i>Nature Reviews Cardiology</i> , 2019, 16, 2-3.	6.1	3
104	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. <i>European Heart Journal</i> , 2020, 41, 1764-1774.	1.0	11
105	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. <i>Angiology</i> , 2020, 71, 105-107.	0.8	11
106	Low bone mass is associated with carotid calcification plaque in Chinese postmenopausal women: the Chongqing osteoporosis study. <i>Climacteric</i> , 2020, 23, 237-244.	1.1	2
107	Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease. , 2020, 205, 107413.		14
108	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
109	Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. <i>Clinical Research in Cardiology</i> , 2020, 109, 315-323.	1.5	39
110	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
111	Atherothrombosis and the NLRP3 inflammasome " endogenous mechanisms of inhibition. <i>Translational Research</i> , 2020, 215, 75-85.	2.2	27

#	ARTICLE	IF	CITATIONS
112	The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900797.	1.5	39
113	Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis. , 2020, 206, 107436.		17
114	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <i>Arthritis and Rheumatology</i> , 2020, 72, 4-6.	2.9	7
115	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 685-701.	1.7	12
116	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
117	Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 24-26.	0.8	1
118	Radionuclide Image-Guided Repair of the Heart. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2415-2429.	2.3	29
119	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 33-47.	1.9	8
120	A Compendium of the Biological Effects of Apolipoprotein A-I_{Milano}. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 54-62.	1.3	11
121	Inflammation and atherosclerosis: what is on the horizon?. <i>Heart</i> , 2020, 106, 80-85.	1.2	61
122	rs1883832: a CD40 single-nucleotide polymorphism for predicting coronary heart disease in humans. <i>Cardiovascular Research</i> , 2020, 116, 1095-1096.	1.8	4
123	Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 472-478.	2.3	49
124	Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13195.	1.7	28
125	Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. <i>European Heart Journal</i> , 2020, 41, 2983-2996.	1.0	108
126	Mediation of Cardiac Macrophage Activity via Auricular Vagal Nerve Stimulation Ameliorates Cardiac Ischemia/Reperfusion Injury. <i>Frontiers in Neuroscience</i> , 2020, 14, 906.	1.4	6
127	Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. <i>Current Atherosclerosis Reports</i> , 2020, 22, 75.	2.0	27
128	Secondary prevention after CABG: do new agents change the paradigm?. <i>Current Opinion in Cardiology</i> , 2020, 35, 664-672.	0.8	5
129	Role of Bempedoic Acid in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 376-388.	0.8	6

#	ARTICLE	IF	CITATIONS
130	Association of trimethylamine <i>N</i> -Oxide with cardiovascular and all-cause mortality in hemodialysis patients. <i>Renal Failure</i> , 2020, 42, 1004-1014.	0.8	19
131	Atherosclerosis and inflammation. New therapeutic approaches. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 256-262.	0.1	17
132	Arteriosclerosis e inflamaci3n. Nuevos enfoques terap4uticos. <i>Medicina Clínica</i> , 2020, 155, 256-262.	0.3	33
133	Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13424.	1.7	15
134	Managing HIV-associated inflammation and ageing in the era of modern ART. <i>HIV Medicine</i> , 2020, 21, 2-16.	1.0	28
135	Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100629.	0.5	8
136	Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?. <i>Antioxidants</i> , 2020, 9, 935.	2.2	31
137	Tolerogenic vaccines for the treatment of cardiovascular diseases. <i>EBioMedicine</i> , 2020, 57, 102827.	2.7	5
138	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232093852.	1.1	19
139	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	0.9	18
140	Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8729.	1.8	16
141	Colchicine for Secondary Cardiovascular Prevention in Coronary Disease. <i>Circulation</i> , 2020, 142, 1901-1904.	1.6	19
142	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 173, 166-167.	2.0	5
143	Atherosclerosis in Rheumatology: Old and New Insights. , 0, , .		0
144	Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?. <i>Journal of the American Heart Association</i> , 2020, 9, e019395.	1.6	12
145	Carotid artery stenosis and inflammatory biomarkers: the role of inflammation-induced immunological responses affecting the vascular systems. <i>Annals of Translational Medicine</i> , 2020, 8, 1276-1276.	0.7	20
146	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
147	A Call to Systematically Monitor for Adverse Events in Users of Low-Dose Methotrexate Therapy. <i>Annals of Internal Medicine</i> , 2020, 172, 425.	2.0	3

#	ARTICLE	IF	CITATIONS
148	EGFP-EGF1-conjugated poly (lactic-co-glycolic acid) nanoparticles as a carrier for the delivery of CCR2 shRNA to atherosclerotic macrophage in vitro. <i>Scientific Reports</i> , 2020, 10, 19636.	1.6	14
149	The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders. <i>Cells</i> , 2020, 9, 1812.	1.8	47
150	Inflammasomes: a preclinical assessment of targeting in atherosclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 825-844.	1.5	8
151	Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. <i>Journal of Hypertension</i> , 2020, 38, 1682-1698.	0.3	102
152	Targeting Inflammation After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2020, 22, 110.	1.3	19
153	Immunity, inflammation and the vasculature in the COVID-19 era. <i>Journal of Hypertension</i> , 2020, 38, 1701-1702.	0.3	6
154	The role of interferon- β in cardiovascular disease: an update. <i>Inflammation Research</i> , 2020, 69, 975-988.	1.6	31
155	Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 170-179.	6.6	22
156	Cohort profile: BIOVASC-late, a prospective multicentred study of imaging and blood biomarkers of carotid plaque inflammation and risk of late vascular recurrence after non-severe stroke in Ireland. <i>BMJ Open</i> , 2020, 10, e038607.	0.8	4
157	A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. <i>Atherosclerosis</i> , 2020, 309, 16-26.	0.4	77
158	Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE ^{-/-} Mice via Nanoformulated Lipid-Methotrexate Conjugates. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 37943-37956.	4.0	21
159	Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2480.	1.0	16
160	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 2065-2071.	2.9	26
161	Modeling early stage atherosclerosis in a primary human vascular microphysiological system. <i>Nature Communications</i> , 2020, 11, 5426.	5.8	38
162	Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2020, 10, 18663.	1.6	10
163	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	2.3	10
164	Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1107-1115.	0.9	12
165	Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 139-146.	0.3	6

#	ARTICLE	IF	CITATIONS
166	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE, 2020, 15, e0237665.	1.1	29
167	Targeting Inflammation to Reduce Residual Cardiovascular Risk. Current Atherosclerosis Reports, 2020, 22, 66.	2.0	29
168	Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatology International, 2020, 40, 1741-1751.	1.5	34
169	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. Current Atherosclerosis Reports, 2020, 22, 67.	2.0	15
170	Residual inflammatory risk: Lessons from trials for the future. Atherosclerosis, 2020, 311, 103-104.	0.4	2
171	Immune Modulation of Coronary Atherosclerosis With Anticytokine Treatment. Circulation: Cardiovascular Imaging, 2020, 13, e011451.	1.3	3
172	Total Burden of Events. Journal of the American College of Cardiology, 2020, 76, 1671-1673.	1.2	1
173	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020, 383, 1838-1847.	13.9	1,010
174	Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?. Arthritis Research and Therapy, 2020, 22, 213.	1.6	9
175	Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation. Current Cardiology Reports, 2020, 22, 119.	1.3	22
176	Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression. Nature Immunology, 2020, 21, 1194-1204.	7.0	115
177	Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	31
178	Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. European Heart Journal, 2020, 41, 3564-3575.	1.0	52
179	<p>Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions</p>. Journal of Multidisciplinary Healthcare, 2020, Volume 13, 621-633.	1.1	22
180	Neural Control of Immunity in Hypertension: Council on Hypertension Mid Career Award for Research Excellence, 2019. Hypertension, 2020, 76, 622-628.	1.3	18
181	Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction. Cells, 2020, 9, 1894.	1.8	13
182	The role of intracoronary imaging in translational research. Cardiovascular Diagnosis and Therapy, 2020, 10, 1480-1507.	0.7	3
183	The Neuro-Inflammatory-Vascular Circuit: Evidence for a Sex-Dependent Interrelation?. Frontiers in Neuroscience, 2020, 14, 614345.	1.4	6

#	ARTICLE	IF	CITATIONS
184	Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. <i>Basic Research in Cardiology</i> , 2020, 115, 78.	2.5	37
186	T Cells in Autoimmunity-Associated Cardiovascular Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 588776.	2.2	24
187	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 347-362.	1.3	23
188	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 582826.	1.1	3
189	Treating Inflammation Prior to Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009127.	1.4	9
190	The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1021-1029.	0.9	11
191	Beyond skin deep: addressing comorbidities in psoriasis. <i>Medical Journal of Australia</i> , 2020, 212, 528-534.	0.8	30
192	Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2020, 2020, CD012825.	1.5	10
193	The association of innate and adaptive immunity, subclinical atherosclerosis, and cardiovascular disease in the Rotterdam Study: A prospective cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003115.	3.9	29
194	Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 15, 820-830.	0.3	0
195	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	1.1	82
196	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 361-379.	3.5	119
197	Vulnerable plaques and patients: state-of-the-art. <i>European Heart Journal</i> , 2020, 41, 2997-3004.	1.0	98
198	Apabetalone â€”ÂBET protein inhibition in cardiovascular disease and Type 2 diabetes. <i>Future Cardiology</i> , 2020, 16, 385-395.	0.5	6
199	Heart Failure Risk Associated With Rheumatoid Arthritisâ€”Related Chronic Inflammation. <i>Journal of the American Heart Association</i> , 2020, 9, e014661.	1.6	56
200	Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 64.	1.1	39
201	Colchicine Use and Incident Coronary Artery Disease inÂMale Patients With Gout. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1722-1728.	0.8	18
202	Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1182-1188.	0.5	16

#	ARTICLE	IF	CITATIONS
203	Metabolic Inflammation and Insulin Resistance in Obesity. <i>Circulation Research</i> , 2020, 126, 1549-1564.	2.0	438
204	Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 991-993.	0.5	17
205	Sex Differences in Proatherogenic Cytokine Levels. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3861.	1.8	34
206	Reducing residual cardiovascular risk with novel therapies. <i>Current Opinion in Lipidology</i> , 2020, 31, 108-110.	1.2	7
207	Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 274-279.	0.4	9
208	Coronary and Peripheral Artery Plaques: Do Differences in Plaque Characteristics Translate to Differences in Lipid Management?. <i>Journal of Investigative Medicine</i> , 2020, 68, 1141-1151.	0.7	9
209	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease's ABC's Approach. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100027.	1.3	6
210	Targeting cardiovascular inflammation: next steps in clinical translation. <i>European Heart Journal</i> , 2021, 42, 113-131.	1.0	186
211	Inflammation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1324-1340.	1.2	273
212	From CANTOS to CIRT to COLCOT to Clinic. <i>Circulation</i> , 2020, 141, 787-789.	1.6	77
213	Cytokines at the Interplay Between Asthma and Atherosclerosis?. <i>Frontiers in Pharmacology</i> , 2020, 11, 166.	1.6	22
214	Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?. <i>Biochemical Pharmacology</i> , 2020, 177, 113894.	2.0	8
215	Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-13.	1.9	323
216	Something old, something new: a paradigm for considering immune therapies for cardiovascular disease. <i>Cardiovascular Research</i> , 2020, 116, e51-e53.	1.8	2
217	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. <i>European Heart Journal</i> , 2020, 41, 2952-2961.	1.0	72
219	Management of ANCA associated vasculitis. <i>BMJ, The</i> , 2020, 368, m421.	3.0	54
220	Role of Colchicine in Stroke Prevention: An Updated Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104756.	0.7	29
221	Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis. <i>Cells</i> , 2020, 9, 584.	1.8	67

#	ARTICLE	IF	CITATIONS
222	E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 106.	1.1	5
223	Methotrexate: what are the true risks of treatment?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1267-1268.	0.5	4
224	Colchicine for acute and chronic coronary syndromes. <i>Heart</i> , 2020, 106, 1555-1560.	1.2	38
225	Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0235637.	1.1	18
226	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1136.	3.0	59
227	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	2.9	126
228	The Fungal Iron Chelator Desferricoprofen Inhibits Atherosclerotic Plaque Formation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4746.	1.8	7
229	ATP-sensitive potassium channels gene polymorphism rs1799858 affects the risk of macro-/micro-vascular arteriosclerotic event in patients with increased low-density lipoprotein cholesterol levels. <i>Lipids in Health and Disease</i> , 2020, 19, 147.	1.2	3
230	Platelets as therapeutic targets to prevent atherosclerosis. <i>Atherosclerosis</i> , 2020, 307, 97-108.	0.4	47
231	Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. <i>International Journal of Dermatology</i> , 2020, 59, 1043-1056.	0.5	19
232	The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. <i>Immunology</i> , 2020, 160, 10-23.	2.0	7
233	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1695-1706.	1.3	57
234	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. <i>Frontiers in Immunology</i> , 2019, 10, 3096.	2.2	122
235	The relationships between cancer and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101472.	1.4	30
237	Atherosclerosis Immunoimaging by Positron Emission Tomography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 865-873.	1.1	18
238	Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001032.	1.8	21
239	High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 176-185.	0.5	76
240	Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. <i>Rheumatology</i> , 2020, 59, 2847-2856.	0.9	30

#	ARTICLE	IF	CITATIONS
241	Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E278-E286.	0.7	1
242	Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 744-757.	1.1	41
243	Reflections on "older" drugs: learning new lessons in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 179-183.	3.5	13
244	Inflammation, Autoimmunity, Infection, and Stroke. <i>Stroke</i> , 2020, 51, 711-718.	1.0	67
245	Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1324-1335.e2.	2.4	72
246	Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a nested case-control study. <i>British Journal of Dermatology</i> , 2020, 183, 684-691.	1.4	15
247	Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection. <i>Journal of the American Heart Association</i> , 2020, 9, e014873.	1.6	33
248	Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 807.	1.8	28
249	Recombinant <i>Lactococcus lactis</i> Expressing Ling Zhi 8 Protein Ameliorates Nonalcoholic Fatty Liver and Early Atherogenesis in Cholesterol-Fed Rabbits. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	17
250	The role of hepcidin and iron homeostasis in atherosclerosis. <i>Pharmacological Research</i> , 2020, 153, 104664.	3.1	64
251	Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 3.	2.0	6
252	Inflamm-aging: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 2974-2982.	1.0	185
253	Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 53.	1.1	72
254	Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. <i>Pharmacotherapy</i> , 2020, 40, 575-583.	1.2	3
255	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: further evidence fuelling the dual target concept. <i>European Heart Journal</i> , 2020, 41, 2962-2964.	1.0	10
256	The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine. <i>Journal of Nuclear Medicine</i> , 2020, 61, 951-961.	2.8	31
257	Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium. <i>Journal of Immunology</i> , 2020, 204, 2995-3007.	0.4	55
258	A perspective on targeting inflammation and cytokine actions in atherosclerosis. <i>Future Medicinal Chemistry</i> , 2020, 12, 613-626.	1.1	15

#	ARTICLE	IF	CITATIONS
259	Anti-inflammatory Therapy in Rheumatoid Arthritis to Improve Cardiovascular Outcome. Canadian Journal of Cardiology, 2020, 36, 1700-1702.	0.8	2
260	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. Atherosclerosis, 2020, 301, 37-43.	0.4	24
261	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 2020, 120, 538-564.	1.8	64
262	Cancer risk in patients with psoriasis: should we be paying more attention?. Expert Review of Clinical Immunology, 2020, 16, 479-492.	1.3	24
263	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circulation Research, 2020, 126, 1260-1280.	2.0	391
264	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. Angiology, 2020, 71, 689-697.	0.8	19
265	Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis. Journal of Clinical Medicine, 2020, 9, 978.	1.0	23
266	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2020, 9, 1033.	1.0	4
267	Identification of Potential Hub Genes of Atherosclerosis Through Bioinformatic Analysis. Journal of Computational Biology, 2021, 28, 60-78.	0.8	4
268	The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease. Journal of Cardiovascular Translational Research, 2021, 14, 13-22.	1.1	34
269	Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model. Journal of Cardiovascular Translational Research, 2021, 14, 150-160.	1.1	19
270	Role of Periodontal Infection, Inflammation and Immunity in Atherosclerosis. Current Problems in Cardiology, 2021, 46, 100638.	1.1	13
271	Mechanisms of vascular damage in systemic lupus erythematosus. , 2021, , 325-331.		0
272	Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study. Journal of Rheumatology, 2021, 48, 361-366.	1.0	5
273	Cardiovascular disease in systemic lupus erythematosus: an update. , 2021, , 415-426.		0
274	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality. JAMA Cardiology, 2021, 6, 587.	3.0	35
275	Metabolic Inflammation in Obesity At the Crossroads between Fatty Acid and Cholesterol Metabolism. Molecular Nutrition and Food Research, 2021, 65, e1900482.	1.5	19
276	Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation. Journal of Cardiovascular Translational Research, 2021, 14, 3-12.	1.1	16

#	ARTICLE	IF	CITATIONS
277	Inflammatory Diseases and Vitamin Eâ€”What Do We Know and Where Do We Go?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000097.	1.5	27
278	Inflammation and cardiovascular diseases: lessons from seminal clinical trials. <i>Cardiovascular Research</i> , 2021, 117, 411-422.	1.8	59
279	Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 333-359.	4.2	15
280	Combating Inflammation in Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2021, 30, 197-206.	0.2	39
281	The Role of Colchicine in Coronary Artery Disease. <i>Current Problems in Cardiology</i> , 2021, 46, 100690.	1.1	3
282	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. <i>Atherosclerosis</i> , 2021, 316, 58-65.	0.4	26
283	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021, 72, 447-458.	5.0	12
284	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
285	Updating concepts on atherosclerotic inflammation: From pathophysiology to treatment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13467.	1.7	22
286	Prevalence and prognostic impact of hsCRP elevation are ageâ€”dependent in women but not in men undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E936-E944.	0.7	3
287	BTS Clinical Statement on pulmonary sarcoidosis. <i>Thorax</i> , 2021, 76, 4-20.	2.7	90
288	A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 238-241.	1.4	12
289	GlycA for long-term outcome in T2DM secondary prevention. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108583.	1.1	6
290	Immunological mechanisms underlying sterile inflammation in the pathogenesis of atherosclerosis: potential sites for intervention. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 37-50.	1.3	6
291	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
292	Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2021, 140, 33-38.	0.7	40
293	Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). <i>Journal of Rheumatology</i> , 2021, 48, 767-774.	1.0	33
294	Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation. <i>Journal of Investigative Dermatology</i> , 2021, 141, 586-595.e5.	0.3	51

#	ARTICLE	IF	CITATIONS
295	Trends of Cardiac Complications in Patients With Rheumatoid Arthritis: Analysis of the United States National Inpatient Sample; 2005-2014. <i>Current Problems in Cardiology</i> , 2021, 46, 100455.	1.1	19
296	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
297	Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110324.	1.2	8
298	Update on the Inflammatory Hypothesis of Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 6.	1.3	14
299	Cardiovascular Side Effects of Medications for Skin Diseases. , 2021, , 391-418.		0
300	Inflammation as a determinant of healing response after coronary stent implantation. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 791-801.	0.7	12
301	Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 487-496.	1.0	8
302	Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 631398.	1.1	14
303	Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001235.	1.8	20
304	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. <i>Current Pharmaceutical Design</i> , 2021, 27, 263-275.	0.9	27
305	Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease. <i>Cells</i> , 2021, 10, 440.	1.8	13
306	Assessing Cardiovascular Risk by Using the Fat Attenuation Index in Coronary CT Angiography. <i>Radiology: Cardiothoracic Imaging</i> , 2021, 3, e200563.	0.9	29
307	Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e24579.	0.4	10
308	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	1.3	6
309	The tandem stenosis mouse model: Towards understanding, imaging, and preventing atherosclerotic plaque instability and rupture. <i>British Journal of Pharmacology</i> , 2022, 179, 979-997.	2.7	14
310	Experimental Agents for the Treatment of Atherosclerosis: New Directions. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 161-179.	1.5	9
311	A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV. <i>Aids</i> , 2021, 35, 1041-1050.	1.0	10
312	Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3398-3412.	1.8	3

#	ARTICLE	IF	CITATIONS
313	A strategy to prevent atherosclerosis via TNF receptor regulation. <i>FASEB Journal</i> , 2021, 35, e21391.	0.2	15
315	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	1.8	54
316	Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1179-1192.	2.4	16
317	Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations. <i>Journal of Rheumatology</i> , 2021, 48, 793-795.	1.0	1
318	Colchicine in ischemic heart disease: the good, the bad and the ugly. <i>Clinical Research in Cardiology</i> , 2021, 110, 1531-1542.	1.5	22
319	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
320	Managing Cardiovascular Risk in Patients with Rheumatic Disease. <i>Medical Clinics of North America</i> , 2021, 105, 247-262.	1.1	9
321	Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature. <i>Current Problems in Cardiology</i> , 2021, 47, 100840.	1.1	1
322	Profiles of Immune Cell Infiltration in Carotid Artery Atherosclerosis Based on Gene Expression Data. <i>Frontiers in Immunology</i> , 2021, 12, 599512.	2.2	14
323	Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. <i>Hypertension</i> , 2021, 77, 856-867.	1.3	44
324	Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3092.	1.8	30
325	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021, 7, e001560.	1.8	2
326	Effect of disease modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2021, 11, 6627.	1.6	8
327	Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular disease. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111467.	2.2	14
328	Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?. <i>European Heart Journal</i> , 2021, 42, 2776-2779.	1.0	4
329	NLRP3 Inflammasome as a Common Denominator of Atherosclerosis and Abdominal Aortic Aneurysm. <i>Circulation Journal</i> , 2021, 85, 2129-2136.	0.7	11
330	System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003196.	1.6	7
331	Two Gut Microbiota-Derived Toxins Are Closely Associated with Cardiovascular Diseases: A Review. <i>Toxins</i> , 2021, 13, 297.	1.5	12

#	ARTICLE	IF	CITATIONS
333	Editorial commentary: A new era for preventive cardiology. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 195-197.	2.3	0
334	The changing landscape of atherosclerosis. <i>Nature</i> , 2021, 592, 524-533.	13.7	921
335	Lactoferrin for the treatment of age-associated inflammation – A pilot study. <i>Physiology International</i> , 2021, , .	0.8	1
336	Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials. <i>European Cardiology Review</i> , 2021, 16, e15.	0.7	8
337	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. <i>JCI Insight</i> , 2021, 6, .	2.3	33
338	Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. <i>Autoimmunity Reviews</i> , 2021, 20, 102778.	2.5	47
339	Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. <i>Cells</i> , 2021, 10, 881.	1.8	29
340	Arterial wall inflammation in rheumatoid arthritis is reduced by anti-inflammatory treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 457-463.	1.6	9
341	Statins in patients with acute ischemic stroke: when we should start therapy?. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 16-28.	0.1	4
342	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	3.5	57
343	The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. <i>Blood</i> , 2021, 137, 2152-2160.	0.6	51
344	Risk factors for hypertension in rheumatoid arthritis patients – A systematic review. <i>Autoimmunity Reviews</i> , 2021, 20, 102786.	2.5	21
345	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	2.3	56
346	Clonal haematopoiesis of emerging significance. <i>Pathology</i> , 2021, 53, 300-311.	0.3	9
347	IL-6 as a Mediator of the Association Between Traditional Risk Factors and Future Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1570-1579.	1.1	10
348	Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2021, 10, e018290.	1.6	8
349	Current advances in the treatment of autoimmune-associated interstitial lung diseases. <i>Journal of the Korean Medical Association</i> , 2021, 64, 264-276.	0.1	0
350	Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. <i>ACR Open Rheumatology</i> , 2021, 3, 371-380.	0.9	8

#	ARTICLE	IF	CITATIONS
351	Inflammation and Cardiovascular Disease: The Future. <i>European Cardiology Review</i> , 2021, 16, e20.	0.7	48
352	Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1728-1746.	2.0	238
353	Targeting inflammation in atherosclerosis – from experimental insights to the clinic. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 589-610.	21.5	459
354	Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1385-1392.	0.5	19
355	Looking for the Achilles heel of atheromatosis: could it be immunotherapy?. <i>Immunotherapy</i> , 2021, 13, 557-560.	1.0	2
356	IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2021, 397, 2060-2069.	6.3	268
357	Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 641955.	1.3	6
358	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. <i>European Cardiology Review</i> , 2021, 16, e18.	0.7	31
359	Interplay between inflammation and thrombosis in cardiovascular pathology. <i>Nature Reviews Cardiology</i> , 2021, 18, 666-682.	6.1	337
360	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	2.0	93
361	The Fractalkine Receptor CX3CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling. <i>Frontiers in Immunology</i> , 2021, 12, 605857.	2.2	10
362	Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. <i>Current Atherosclerosis Reports</i> , 2021, 23, 32.	2.0	11
363	Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 177-185.	1.5	8
364	The Association Between Psoriasis and Cardiovascular Diseases. <i>European Cardiology Review</i> , 2021, 16, e19.	0.7	9
365	Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). <i>Future Cardiology</i> , 2021, 17, 411-414.	0.5	10
366	Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 659-668.	1.0	3
367	Cardiovascular disease and depression in psoriatic arthritis: Multidimensional comorbidities requiring multidisciplinary management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101689.	1.4	8
368	Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2038-2048.	1.1	48

#	ARTICLE	IF	CITATIONS
369	Sexually Dimorphic Relationships Among Saa3 (Serum Amyloid A3), Inflammation, and Cholesterol Metabolism Modulate Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e299-e313.	1.1	10
370	Efficacy and Safety of Colchicine in Postâ€“acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676771.	1.1	6
371	Association between miR-146a and Tumor Necrosis Factor Alpha (TNF-Î±) in Stable Coronary Artery Disease. <i>Medicina (Lithuania)</i> , 2021, 57, 575.	0.8	4
372	Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohort. <i>Journal of Dermatological Treatment</i> , 2021, , 1-7.	1.1	0
373	Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2539.	1.0	16
374	Inflammation in heart disease: do researchers know enough?. <i>Nature</i> , 2021, 594, S8-S9.	13.7	3
375	Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. <i>Journal of Clinical Lipidology</i> , 2021, 15, 556-568.	0.6	17
376	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
377	Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021120.	1.6	10
378	Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. <i>Current Opinion in Cardiology</i> , 2021, 36, 609-615.	0.8	6
379	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	1.0	5
380	Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	0
381	Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7061.	1.8	37
382	Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. <i>Clinical Drug Investigation</i> , 2021, 41, 667-674.	1.1	6
383	Treg cells in atherosclerosis. <i>Molecular Biology Reports</i> , 2021, 48, 4897-4910.	1.0	23
384	The Role of Colchicine in Atherosclerotic Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2021, 30, 795-806.	0.2	12
385	High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome. <i>Scientific Reports</i> , 2021, 11, 11444.	1.6	12
386	Psoriasis and coronary heart diseaseâ€“not as severe as predicted. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 388-392.	0.2	5

#	ARTICLE	IF	CITATIONS
387	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	1.1	9
388	Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1105-1112.	1.3	12
389	Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 271-278.	0.2	5
390	Effect of anti-inflammatory therapy on major cardiovascular events in patients with diabetes: A meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102164.	1.8	5
391	A Risk Score for Predicting Long-Term Mortality Following Off-Pump Coronary Artery Bypass Grafting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3032.	1.0	16
392	Long-term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E655-E660.	0.7	4
393	Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8087-8094.	1.6	14
394	The Role of C-reactive Protein in Patient Risk Stratification and Treatment. <i>European Cardiology Review</i> , 2021, 16, e28.	0.7	7
395	Immune cell profiling in atherosclerosis: role in research and precision medicine. <i>Nature Reviews Cardiology</i> , 2022, 19, 43-58.	6.1	58
396	New insight into biology, molecular diagnostics and treatment options of unstable carotid atherosclerotic plaque: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1207-1207.	0.7	16
397	Cardiovascular Outcomes in the Patients With Primary Central Nervous System Lymphoma: A Multi-Registry Based Cohort Study of 4,038 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 691038.	1.3	4
398	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, ...	0.1	4
399	The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2022, 30, 47-57.	0.3	5
400	Colchicine in the Management of Acute and Chronic Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 120.	1.3	3
401	Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 669-679.	10.6	16
402	Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 372-379.	0.7	17
403	Browning of adipose tissue and increased thermogenesis induced by Methotrexate. <i>FASEB BioAdvances</i> , 2021, 3, 877-887.	1.3	2
404	Tertiary lymphoid tissues: a regional hub for kidney inflammation. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 26-33.	0.4	11

#	ARTICLE	IF	CITATIONS
405	Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. <i>Pharmacological Research</i> , 2021, 169, 105689.	3.1	29
406	A Low-Sodium DASH Dietary Pattern Affects Serum Markers of Inflammation and Mineral Metabolism in Adults with Elevated Blood Pressure. <i>Journal of Nutrition</i> , 2021, 151, 3067-3074.	1.3	2
407	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	1.0	61
408	Role of inflammation and immunity in atherosclerosis and possible ways of their control. <i>Vnitřní Lekarství</i> , 2021, 67, 304-308.	0.1	0
409	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
410	Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. <i>Inflammopharmacology</i> , 2021, 29, 1379-1387.	1.9	23
411	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
412	Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 726341.	1.1	6
413	Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential. <i>Journal of Clinical Medicine</i> , 2021, 10, 3825.	1.0	14
414	Glucocorticoid induced TNF receptor family-related protein (GITR) – A novel driver of atherosclerosis. <i>Vascular Pharmacology</i> , 2021, 139, 106884.	1.0	3
415	Molecular Aspects of Lifestyle and Environmental Effects in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 481-495.	1.2	2
416	Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. <i>International Journal of Cardiology</i> , 2021, 337, 21-27.	0.8	19
417	Cardiovascular Risk Associated with Methotrexate versus Retinoids in Patients with Psoriasis: A Nationwide Taiwanese Cohort Study. <i>Clinical Epidemiology</i> , 2021, Volume 13, 693-705.	1.5	7
418	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	3.0	43
419	Redefining residual inflammatory risk after acute coronary syndrome. <i>Future Cardiology</i> , 2022, 18, 115-123.	0.5	2
420	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	9
421	Inflammation and ischemic heart disease: The next therapeutic target?. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 785-796.	0.2	9
422	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87

#	ARTICLE	IF	CITATIONS
423	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. Netherlands Heart Journal, 2022, 30, 25-37.	0.3	3
424	DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A2 in human vulnerable atherosclerotic plaque. Clinical Epigenetics, 2021, 13, 161.	1.8	16
425	Single cell analyses to understand the immune continuum in atherosclerosis. Atherosclerosis, 2021, 330, 85-94.	0.4	18
426	Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation. Cardiovascular Drugs and Therapy, 2022, 36, 1075-1089.	1.3	17
427	Resident Macrophages and Their Potential in Cardiac Tissue Engineering. Tissue Engineering - Part B: Reviews, 2022, 28, 579-591.	2.5	12
428	Inflammation and Stroke Risk: A New Target for Prevention. Stroke, 2021, 52, 2697-2706.	1.0	78
429	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
430	Low-intensity pulsed ultrasound therapy suppresses coronary adventitial inflammatory changes and hyperconstricting responses after coronary stent implantation in pigs in vivo. PLoS ONE, 2021, 16, e0257175.	1.1	3
431	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy. Current Opinion in Cardiology, 2021, Publish Ahead of Print, 776-783.	0.8	1
432	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3197-3207.	3.0	11
433	Colchicine reduces atherosclerotic plaque vulnerability in rabbits. Atherosclerosis Plus, 2021, 45, 1-9.	0.3	6
434	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. International Journal of Women's Dermatology, 2021, 7, 560-575.	1.1	7
435	Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. Atherosclerosis, 2021, 335, 98-109.	0.4	8
436	Bacterial lipopolysaccharide "Stoking the fire of residual risk?. Trends in Cardiovascular Medicine, 2021, , .	2.3	0
437	Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 1520-1528.	1.1	17
438	The role and transformative potential of IL-19 in atherosclerosis. Cytokine and Growth Factor Reviews, 2021, 62, 70-82.	3.2	9
439	Management of inflammation in cardiovascular diseases. Pharmacological Research, 2021, 173, 105912.	3.1	39
440	Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway. ELife, 2021, 10, .	2.8	9

#	ARTICLE	IF	CITATIONS
441	Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110277.	1.2	8
442	Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome. <i>Current Cardiology Reviews</i> , 2021, 16, 333-337.	0.6	5
443	Colchicine and the heart: old friends, old foes. <i>Rheumatology</i> , 2021, 60, 2035-2036.	0.9	3
444	Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2021, 15, 175394472110427.	1.0	0
445	The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. <i>European Heart Journal</i> , 2021, 42, 896-903.	1.0	152
446	Perivascular Adipose Tissue and Atherosclerosis. <i>Contemporary Cardiology</i> , 2020, , 91-115.	0.0	1
447	A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 75-87.	1.1	8
448	Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 63-74.	1.1	9
449	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	3.1	56
450	Terapias antiinflamatorias para la enfermedad cardiovascular: vías de señalización y mecanismos. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 767-773.	0.6	11
451	The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice. <i>Biochemical Journal</i> , 2020, 477, 2347-2361.	1.7	26
452	How does methotrexate work?. <i>Biochemical Society Transactions</i> , 2020, 48, 559-567.	1.6	48
453	Inflammation in Atherosclerosis- No Longer a Theory. <i>Clinical Chemistry</i> , 2021, 67, 131-142.	1.5	158
454	The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. <i>Cardiology in Review</i> , 2021, 29, 178-183.	0.6	2
455	Colchicine therapy in patients with coronary artery disease. <i>Coronary Artery Disease</i> , 2020, Publish Ahead of Print, 441-447.	0.3	9
456	Macrophage Efferocytosis in Cardiac Pathophysiology and Repair. <i>Shock</i> , 2021, 55, 177-188.	1.0	17
459	Anti-inflammatory therapy for cardiovascular disease. <i>Annals of Translational Medicine</i> , 2019, 7, 147-147.	0.7	40
460	Macrophage: A Key Therapeutic Target in Atherosclerosis?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3165-3174.	0.9	21

#	ARTICLE	IF	CITATIONS
461	Methotrexate and Vasculoprotection: Mechanistic Insights and Potential Therapeutic Applications in Old Age. <i>Current Pharmaceutical Design</i> , 2019, 25, 4175-4184.	0.9	9
462	Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2020, 26, 2565-2573.	0.9	22
463	Pro-inflammatory Cytokines in Acute Coronary Syndromes. <i>Current Pharmaceutical Design</i> , 2020, 26, 4624-4647.	0.9	23
464	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). <i>Current Vascular Pharmacology</i> , 2020, 18, 455-462.	0.8	4
465	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. <i>Current Vascular Pharmacology</i> , 2020, 18, 549-565.	0.8	61
466	Influence of Local Myocardial Infarction on Endothelial Function, Neointimal Progression, and Inflammation in Target and Non-Target Vascular Territories in a Porcine Model of Acute Myocardial Infarction. <i>Journal of Korean Medical Science</i> , 2019, 34, e145.	1.1	4
467	A New Strategy for the Treatment of Atherothrombosis – Inhibition of Inflammation. <i>Physiological Research</i> , 2019, 68, S17-S30.	0.4	8
468	Targeting the Inflammation Culprit in Patients with Psoriasis/Psoriatic Arthritis and Associated Cardiovascular Comorbidities. Is the IL-17 Inhibitor the New Kid on the Block?. <i>World Journal of Cardiovascular Diseases</i> , 2019, 09, 267-294.	0.0	1
469	Methotrexate: CIRTified for preventing atherosclerotic events?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2019, 49, 136-138.	0.2	2
470	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 787-891.	0.3	102
471	IL-1 β in atherosclerotic vascular calcification: From bench to bedside. <i>International Journal of Biological Sciences</i> , 2021, 17, 4353-4364.	2.6	11
472	Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?. <i>American Heart Journal Plus</i> , 2021, 9, 100057.	0.3	0
473	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021, 23, E13-E18.	0.0	10
474	Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis. , 2021, 25, 753-761.		5
475	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768119.	1.1	24
476	Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 503-510.	1.4	37
477	Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. <i>Cardiovascular Research</i> , 2021, 117, 2589-2609.	1.8	25
478	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28

#	ARTICLE	IF	CITATIONS
479	Anti-Inflammatory Therapeutics and Coronary Artery Disease. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	1
480	Randomized Trial of Anti-inflammatory Medications and Coronary Endothelial Dysfunction in Patients With Stable Coronary Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 728654.	1.1	3
481	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1242-1250.	1.6	9
482	Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11170.	1.8	34
484	Prevention of cardiovascular event targeted vascular inflammation, and pathology of thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 837-844.	0.1	0
485	Lipidsenkende Mittel. , 2019, , 749-760.		0
486	Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca. <i>REC: CardioClinics</i> , 2019, 54, 44-50.	0.1	0
489	Sedimentasyon & CRP - Geşmişten Geleceğe. <i>Ege Tıp Bilimleri Dergisi</i> , 2019, 2, 85-96.	0.1	1
490	Recent Advance in Atherosclerosis Research. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1607-1616.	0.0	0
491	Drug Discovery for Coronary Artery Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1177, 297-339.	0.8	6
492	Lipidsenkende Mittel. , 2020, , 601-614.		0
493	Old drug, new trick: colchicine for cardiovascular diseases. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2020, 50, 49-50.	0.2	0
494	Predictive value of three Inflammation-based Glasgow Prognostic Scores for major cardiovascular adverse events in patients with acute myocardial infarction during hospitalization: a retrospective study. <i>PeerJ</i> , 2020, 8, e9068.	0.9	8
495	Personalized Therapy of Cardiovascular Disorders. , 2021, , 279-316.		0
496	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 615-636.	0.0	0
497	Is depression associated with the risk of cardiovascular disease or vice versa?. <i>Clinical and Experimental Health Sciences</i> , 0, , .	0.1	0
498	C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 565-583.	0.0	1
499	Inflammation and Atherosclerotic Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2021, , 289-333.	0.0	0

#	ARTICLE	IF	CITATIONS
500	ATIC as a link between antirheumatic drugs and regulation of energy metabolism in skeletal muscle. <i>Periodicum Biologorum</i> , 2020, 121-122, 129-145.	0.1	0
501	Repurposing Drugs for Skin Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 7214-7221.	1.2	5
502	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , 2020, 19, 323-342.	0.8	15
503	Rheumatic Diseases Among Older Adults. , 2020, , 1-12.		0
504	Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-control Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00365.	0.6	5
505	Obesity-Induced Cardiovascular Complications and Therapeutic Intervention. , 2020, , 15-53.		0
506	Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardiaca. REC: <i>CardioClinics</i> , 2020, 55, 18-24.	0.1	0
508	Acute coronary syndrome: how to reduce the residual inflammatory risk?. <i>Russian Journal of Cardiology</i> , 2020, 25, 113-118.	0.4	3
509	Major acute cardiovascular events in patients with inflammatory bowel disease. <i>Coronary Artery Disease</i> , 2021, 32, 73-77.	0.3	6
510	Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 741542.	1.1	10
511	Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 703279.	1.6	1
512	Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). <i>Journal of Translational Medicine</i> , 2021, 19, 460.	1.8	23
514	Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application. <i>International Journal of Cardiovascular Sciences</i> , 2020, , .	0.0	0
515	Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up. <i>Frontiers in Medicine</i> , 2020, 7, 556086.	1.2	1
517	Cardiovascular Disease in Juvenile Idiopathic Arthritis. <i>Current Vascular Pharmacology</i> , 2020, 18, 580-591.	0.8	6
518	Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 512-519.	0.2	5
519	Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2020, 32, 193-199.	0.1	0
520	Efecto del clopidogrel vs. aspirina en la función de la expresión del inflammasoma proaterosclerótico NLRP1 en células endoteliales. Estudio ECLOAS. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 193-199.	0.4	0

#	ARTICLE	IF	CITATIONS
521	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , 2021, 60, 2963-2968.	0.9	3
522	Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, S1-S17.	0.1	1
523	The Role of Microbiologic Agents in the Progression of the Atherosclerosis: a Comprehensive Review. <i>Journal of the Saudi Heart Association</i> , 2020, 32, 440-450.	0.2	0
524	Anti-inflammatory Therapy in Atherosclerosis: The Past and the Future. <i>Cardiology Discovery</i> , 2021, 1, 12-14.	0.6	2
525	Microvascular Ageing Links Metabolic Disease to Age-Related Disorders: The Role of Oxidative Stress and Inflammation in Promoting Microvascular Dysfunction. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, S78-S87.	0.8	17
526	Inflammation and ischemic heart disease: The next therapeutic target?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 785-796.	0.2	5
527	Plasma Metabolome Normalization in Rheumatoid Arthritis Following Initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy. <i>Metabolites</i> , 2021, 11, 824.	1.3	14
529	Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. <i>Nature Reviews Cardiology</i> , 2022, 19, 228-249.	6.1	171
530	âf`è €ç®ç-¾ç-...ã,çš,,ã`ã™¬ç»†èfž. <i>Scientia Sinica Vitae</i> , 2021, , .	0.1	0
531	Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. <i>Rheumatology and Therapy</i> , 2022, 9, 49-71.	1.1	3
532	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2021, , .	0.8	1
533	Nanoparticle theranostics in cardiovascular inflammation. <i>Seminars in Immunology</i> , 2021, 56, 101536.	2.7	13
534	Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 41-48.	1.0	8
535	Statins and Inflammation. <i>Current Atherosclerosis Reports</i> , 2021, 23, 80.	2.0	34
536	Rheumatic Diseases Among Older Adults. , 2021, , 4305-4315.		0
537	The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio. <i>Arthritis Research and Therapy</i> , 2022, 24, 17.	1.6	5
538	Inflammation in obesity, diabetes, and related disorders. <i>Immunity</i> , 2022, 55, 31-55.	6.6	489
539	Triiodothyronine (T3), inflammation and mortality risk in patients with acute myocardial infarction. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	3

#	ARTICLE	IF	CITATIONS
540	Kardiovaskuläre Inflammation: Stand von Klinik und Forschung. , 0, , .		0
541	Using Audiometry to Track Atherosclerosis: Measuring a Beneficial Effect of Methotrexate in Rheumatoid Arthritis. <i>European Medical Journal Rheumatology</i> , 0, , 110-117.	0.0	0
542	Sekundärprävention: Colchicin erneut geprüft. , 0, , .		0
543	The Role of Microbiologic Agents in the Progression of the Atherosclerosis: A comprehensive review. <i>Journal of the Saudi Heart Association</i> , 2020, 32, 440-450.	0.2	0
544	Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 804.	1.8	7
545	Anti-inflammatory strategies for atherosclerotic artery disease. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 661-672.	1.0	4
546	Immunotherapeutic Strategies in Cancer and Atherosclerosis – Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
547	Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials. <i>Heart Lung and Circulation</i> , 2022, 31, 685-695.	0.2	3
548	Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 677-688.	1.0	15
549	Precision medicine to manage chronic immune-related conditions. , 2022, , 295-318.		1
550	Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?. <i>Nature Reviews Cardiology</i> , 2022, 19, 522-542.	6.1	125
551	Immunity, Vascular Aging and Stroke. <i>Current Medicinal Chemistry</i> , 2022, 29, 5510-5521.	1.2	7
552	Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory β -7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-26.	1.9	11
553	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. <i>US Cardiology Review</i> , 0, 16, .	0.5	4
554	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	0.7	4
555	Cost-effectiveness of Canakinumab from a Canadian perspective for recurrent cardiovascular events. <i>CJC Open</i> , 2022, , .	0.7	2
556	Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members. <i>Biomedicines</i> , 2022, 10, 367.	1.4	1
557	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	0.8	7

#	ARTICLE	IF	CITATIONS
558	Relationship between intracoronary thrombus burden and systemic immune-inflammation index in patients with ST-segment elevation myocardial infarction. <i>Acta Cardiologica</i> , 2023, 78, 72-79.	0.3	10
559	Inflammation and the Link to Vascular Brain Health: Timing Is Brain. <i>Stroke</i> , 2022, 53, 427-436.	1.0	17
560	The effect of trehalose administration on vascular inflammation in patients with coronary artery disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112632.	2.5	5
561	Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 746774.	1.1	0
562	IL-6, IL-1 β , and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome. <i>Recent Advances in Inflammation & Allergy Drug Discovery</i> , 2022, 15, 71-79.	0.4	0
563	Anti-inflammatory Strategies in Atherosclerosis. <i>Hamostaseologie</i> , 2021, 41, 433-442.	0.9	11
564	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 151-168.	1.2	10
565	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. <i>Methods in Molecular Biology</i> , 2022, 2419, 3-19.	0.4	9
566	Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation. <i>Methods in Molecular Biology</i> , 2022, 2419, 21-37.	0.4	6
567	Myocardial ischemia-reperfusion injury and the influence of inflammation. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 357-366.	2.3	70
568	Identification of tolerance levels on the cold-water coral <i>Desmophyllum pertusum</i> (<i>Lophelia pertusa</i>) from realistic exposure conditions to suspended bentonite, barite and drill cutting particles. <i>PLoS ONE</i> , 2022, 17, e0263061.	1.1	4
569	Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2426.	1.2	16
570	Prevalence and real-world management of NSTEMI with multivessel disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 1-11.	0.7	9
571	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. <i>Current Diabetes Reports</i> , 2022, 22, 129-136.	1.7	5
572	Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. <i>Biology</i> , 2022, 11, 355.	1.3	32
573	P2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction. <i>Basic Research in Cardiology</i> , 2022, 117, 16.	2.5	5
574	The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 605-615.	1.1	8
575	Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 84.	0.7	8

#	ARTICLE	IF	CITATIONS
576	Inflammation influences thrombus burden in STEMI?. <i>Acta Cardiologica</i> , 2022, , 1-1.	0.3	0
577	Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3133.	1.8	8
578	Targeting the CCL2â€“CCR2 axis for atheroprotection. <i>European Heart Journal</i> , 2022, 43, 1799-1808.	1.0	60
579	Colchicineâ€”regeneration of an old drug. <i>Irish Journal of Medical Science</i> , 2023, 192, 115-123.	0.8	5
580	Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841545.	1.1	17
581	The Controversial Role of HCY and Vitamin B Deficiency in Cardiovascular Diseases. <i>Nutrients</i> , 2022, 14, 1412.	1.7	21
582	Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development. <i>Metabolites</i> , 2022, 12, 333.	1.3	14
583	Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-12.	0.9	1
584	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications. <i>Cardiovascular Research</i> , 2023, 119, 121-135.	1.8	7
585	Pharmacological Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical Studies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATVBAHA122317492.	1.1	8
586	Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. <i>Pharmacological Research</i> , 2022, 178, 106157.	3.1	14
587	Managing Cardiovascular Risk in Patients with Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 429-444.	0.8	4
588	Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis. <i>Nano Today</i> , 2022, 44, 101453.	6.2	19
589	The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3135-3151.	2.7	16
590	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6893-6906.	1.6	8
591	The effect of therapy on subclinical atherosclerosis of the carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 708-714.	0.2	1
592	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 76-83.	0.1	1
593	Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5926.	1.0	2

#	ARTICLE	IF	CITATIONS
594	Monocyte-to-Lymphocyte Ratio as a Predictor of Worse Long-Term Survival after Off-Pump Surgical Revascularization-Initial Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1324.	0.8	3
596	Residual Inflammatory Risk After Percutaneous Coronary Intervention. <i>JACC Asia</i> , 2022, , .	0.5	0
597	Macrophage Dysfunction in Autoimmune Rheumatic Diseases and Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4513.	1.8	9
598	Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2109.	1.0	5
599	Smad3 regulates smooth muscle cell fate and mediates adverse remodeling and calcification of the atherosclerotic plaque. , 2022, 1, 322-333.		21
600	GuÃa ESC 2021 sobre la prevenciÃn de la enfermedad cardiovascular en la prÃctica clÃnica. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 429.e1-429.e104.	0.6	27
601	<scp>Timeâ€Varying</scp> Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. <i>ACR Open Rheumatology</i> , 2022, 4, 587-595.	0.9	8
602	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. <i>Contemporary Clinical Trials</i> , 2022, 117, 106762.	0.8	6
603	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. <i>JACC Asia</i> , 2022, 2, 323-337.	0.5	5
604	Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke. <i>Circulation Research</i> , 2022, 130, 1167-1186.	2.0	74
605	Endothelialâ€Immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease. <i>EMBO Reports</i> , 2022, 23, e54271.	2.0	7
606	Treatment of early rheumatoid arthritis: Methotrexate and beyond. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102227.	1.7	22
608	Metabolism in atherosclerotic plaques: immunoregulatory mechanisms in the arterial wall. <i>Clinical Science</i> , 2022, 136, 435-454.	1.8	8
609	Colchicine in Cardiovascular Disease: In-Depth Review.. <i>Circulation</i> , 2022, 145, 61-78.	1.6	37
610	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003911.	3.9	21
611	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. <i>GeroScience</i> , 2022, 44, 1373-1392.	2.1	36
612	Early Detection of Inflammation-Prone STEMI Patients Using the CRP Troponin Test (CTT). <i>Journal of Clinical Medicine</i> , 2022, 11, 2453.	1.0	5
613	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9

#	ARTICLE	IF	CITATIONS
615	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	5
616	Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. <i>Journal of Clinical Medicine</i> , 2022, 11, 2704.	1.0	18
617	Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry. <i>Joint Bone Spine</i> , 2022, 89, 105401.	0.8	3
619	Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease. <i>Circulation Research</i> , 2022, 130, 1618-1641.	2.0	11
620	Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach. <i>European Journal of Pharmacology</i> , 2022, 925, 174998.	1.7	5
621	New insight into dyslipidemia-induced cellular senescence in atherosclerosis. <i>Biological Reviews</i> , 2022, 97, 1844-1867.	4.7	27
622	The Management of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , .	0.9	1
623	Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light. <i>Cardiovascular Research</i> , 2023, 119, 112-120.	1.8	7
624	Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. <i>Cardiovascular Research</i> , 2023, 119, 1146-1160.	1.8	18
626	Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. <i>Contemporary Cardiology</i> , 2022, , 247-270.	0.0	3
627	The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 819-830.	1.1	10
628	Oxidative Stress in Men with Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: Mechanisms and Management of Reproductive Dysfunction. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 237-256.	0.8	3
629	Modern Concepts in Cardiovascular Disease: Inflamm-Aging. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	12
630	Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease. <i>Journal of Investigative Medicine</i> , 2022, 70, 1433-1437.	0.7	1
633	Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152036.	1.6	1
634	Managing residual inflammatory risk in atherosclerotic cardiovascular disease: another piece of the puzzle?. <i>Cardiology Plus</i> , 2022, 7, 1-2.	0.2	1
635	Identification of Biomarkers Associated With CD8+ T Cells in Coronary Artery Disease and Their Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
636	Animal Models of Atherosclerosis—Supportive Notes and Tricks of the Trade. <i>Circulation Research</i> , 2022, 130, 1869-1887.	2.0	26

#	ARTICLE	IF	CITATIONS
637	Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography. <i>American Heart Journal</i> , 2022, 252, 51-59.	1.2	6
638	Colchicine for Coronary Artery Disease: A Review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
639	Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Annals of Medicine</i> , 2022, 54, 1667-1677.	1.5	37
640	Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression. <i>Circulation Research</i> , 2022, 131, .	2.0	15
641	Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. <i>RMD Open</i> , 2022, 8, e001944.	1.8	9
642	Genetic association and single-cell transcriptome analyses reveal distinct features connecting autoimmunity with cancers. <i>IScience</i> , 2022, 25, 104631.	1.9	3
643	Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6648.	1.8	3
644	Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. , 2022, 237, 108228.		9
645	Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. <i>International Journal of Cardiology</i> , 2022, 363, 20-22.	0.8	5
646	The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	9
647	Early Termination of Clinical Trials for Futility “ Considerations for a Data and Safety Monitoring Board. , 2022, 1, .		3
648	Role of Inflammation in Cardiac Remodeling After Acute Myocardial Infarction. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	12
649	Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
650	Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 639-647.	0.8	2
651	Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 36-46.	1.2	17
653	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-13.	0.6	1
654	Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function in ApoE mice. <i>Atherosclerosis</i> , 2022, 356, 28-40.	0.4	19
655	Management of progressive pulmonary fibrosis associated with connective tissue disease. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 765-774.	1.0	6

#	ARTICLE	IF	CITATIONS
656	Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
657	Treatment of periodontitis and C-reactive protein: A systematic review and meta-analysis of randomized clinical trials. <i>Journal of Clinical Periodontology</i> , 2023, 50, 45-60.	2.3	10
658	Cardiovascular Events and Gout Flares. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 425.	3.8	2
659	Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review. <i>Dermatology and Therapy</i> , 2022, 12, 2201-2216.	1.4	6
660	The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury. <i>Biomedicines</i> , 2022, 10, 1939.	1.4	18
661	Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 ² , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. <i>Circulation</i> , 2022, 146, 372-379.	1.6	66
662	Systemic lupus erythematosus and cardiovascular disease. <i>Journal of Internal Medicine</i> , 2023, 293, 48-62.	2.7	17
663	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. <i>Cardiovascular Research</i> , 2023, 118, 3536-3555.	1.8	29
664	High C-Reactive Protein/Low Serum Albumin: A Hidden Villain in Cardiovascular Disease. <i>Angiology</i> , 2022, 73, 797-799.	0.8	0
665	Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e504-e525.	0.5	5
666	GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100373.	1.3	7
667	SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 501-512.	0.2	3
669	Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?. <i>Current Opinion in Pharmacology</i> , 2022, 66, 102283.	1.7	12
670	Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	29
671	Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
672	Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10617.	1.8	17
673	Gut microbiota-derived metabolites in inflammatory diseases based on targeted metabolomics. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
674	Examining the potential direct cardiovascular benefit of tumor necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2023, 32, 407-415.	0.9	1

#	ARTICLE	IF	CITATIONS
675	Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. <i>Nature Reviews Cardiology</i> , 2023, 20, 181-196.	6.1	28
676	Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
677	The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function. <i>Circulation Research</i> , 2022, 131, 701-712.	2.0	12
678	Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. <i>Nutrients</i> , 2022, 14, 3775.	1.7	2
679	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 762-778.	4.1	51
680	Autoimmune diseases and atherothrombotic risk. <i>Lancet, The</i> , 2022, 400, 708-710.	6.3	0
681	Triterpenoid saponins of <i>Ilex pubescens</i> against TNF- α induced inflammation and apoptosis in human umbilical vein endothelial cells via autophagy pathway. <i>Journal of Pharmacy and Pharmacology</i> , 2022, 74, 1749-1757.	1.2	3
682	Roles of Oxidative Stress and Inflammation in Vascular Endothelial Dysfunction-Related Disease. <i>Antioxidants</i> , 2022, 11, 1958.	2.2	31
683	Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	3
684	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
685	A bibliometric analysis of T cell and atherosclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
686	Interleukin-1 in Coronary Artery Disease. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2368-2389.	1.0	17
687	Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases. <i>Nature Aging</i> , 2022, 2, 956-972.	5.3	11
688	Construction of an immune-related signature for predicting the ischemic events in patients undergoing carotid endarterectomy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
689	Editorial commentary: Immune checkpoint inhibitors and the cardiovascular system: Reflecting on the past and looking towards the future. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 78-79.	2.3	0
690	Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12054.	1.8	9
691	The Role of Inflammation in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12906.	1.8	86
692	Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal. <i>Scientific Reports</i> , 2022, 12, .	1.6	0

#	ARTICLE	IF	CITATIONS
693	Vulnerable Plaque Imaging. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 230-240.	2.5	1
695	Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 β , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". <i>Circulation</i> , 2022, 146, .	1.6	3
696	Therapeutic role of colchicine in reducing cardiovascular risk associated with inflammation. <i>Endocrinología y Nutrición (English Ed)</i> , 2022, .	0.1	0
698	Therapeutic inhibition of MPO stabilizes pre-existing high risk atherosclerotic plaque. <i>Redox Biology</i> , 2022, 58, 102532.	3.9	11
699	Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 324-330.	0.5	21
700	Targeting the reduction of inflammatory risk associated with cardiovascular disease by treating periodontitis either alone or in combination with a systemic anti-inflammatory agent: protocol for a pilot, parallel group, randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e063148.	0.8	2
701	Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
702	Natural products against inflammation and atherosclerosis: Targeting on gut microbiota. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
703	A Potential New Link Between Inflammation and Vascular Calcification. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	3
704	The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15937.	1.8	15
705	Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction. <i>Nature Communications</i> , 2022, 13, .	5.8	5
706	Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. <i>British Journal of Pharmacology</i> , 2023, 180, 685-700.	2.7	5
707	Coronary Flow Reserve, Inflammation, and Myocardial Strain. <i>JACC Basic To Translational Science</i> , 2023, 8, 141-151.	1.9	3
708	Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery. <i>Clinical Science</i> , 2022, 136, 1731-1758.	1.8	4
709	Targeting inflammation in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2023, 32, 111-117.	1.0	4
710	Factors Associated with RANTES, EMMPIRIN, MMP2 and MMP9, and the Association of These Biomarkers with Cardiovascular Disease in a Multi-Ethnic Population. <i>Journal of Clinical Medicine</i> , 2022, 11, 7281.	1.0	1
711	Inflammation specific environment activated methotrexate-loaded nanomedicine to treat rheumatoid arthritis by immune environment reconstruction. <i>Acta Biomaterialia</i> , 2023, 157, 367-380.	4.1	7
712	Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases. <i>Pharmaceuticals</i> , 2023, 16, 78.	1.7	5

#	ARTICLE	IF	CITATIONS
713	Advances in immunotherapy modalities for atherosclerosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
714	Macrophages in cardiac remodelling after myocardial infarction. <i>Nature Reviews Cardiology</i> , 2023, 20, 373-385.	6.1	28
715	Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context. <i>Circulation</i> , 2023, 147, 83-100.	1.6	6
716	Immune Profiling Reveals Decreases in Circulating Regulatory and Exhausted TÂCells in Human Hypertension. <i>JACC Basic To Translational Science</i> , 2023, 8, 319-336.	1.9	9
717	The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 311-317.	1.4	2
718	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. <i>Current Atherosclerosis Reports</i> , 2023, 25, 1-17.	2.0	28
719	Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study. <i>Rheumatology</i> , 2023, 62, 2998-3005.	0.9	2
720	Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy. <i>Life</i> , 2023, 13, 319.	1.1	4
721	Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2079.	1.8	7
722	Genome-wide Association Study of Methotrexate-induced Liver Injury in Rheumatoid Arthritis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 916-923.	2.3	0
723	Advanced therapeutics for targeting atherosclerosis. , 2023, , 93-105.		0
724	White blood cells and coronary heart disease: A mendelian randomization study. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
725	Integrated whole-genome gene expression analysis reveals an atlas of dynamic immune landscapes after myocardial infarction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
726	Prognostic role of <scp>CRP</scp>-independent inflammatory patterns in patients undergoing primary percutaneous interventions. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	1
727	Small vessel disease: Connections between the kidney and the heart. <i>American Heart Journal Plus</i> , 2023, 26, 100257.	0.3	0
728	Expert consensus on the systemic treatment of atopic dermatitis in special populations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1135-1148.	1.3	24
729	Personalised Approach to Atherosclerotic Cardiovascular Disease: The Future is Here. <i>EMJ Cardiology</i> , 0, , 2-10.	0.0	0
730	Cardiovascular Manifestations in Rheumatoid Arthritis. <i>Cardiology in Review</i> , 2024, 32, 146-152.	0.6	1

#	ARTICLE	IF	CITATIONS
731	Herz-Kreislauf-Risiko bei rheumatoider Arthritis: Medikamente reduzieren Entzündungen in Arterien. , 0, , .		0
732	Use of methotrexate and risk of skin cancer: a nationwide caseâ€“control study. <i>British Journal of Cancer</i> , 2023, 128, 1311-1319.	2.9	7
733	JAK inhibitors in rheumatology. <i>Immunological Medicine</i> , 2023, 46, 143-152.	1.4	3
734	Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2023, 12, 1302.	1.0	9
735	Chronic rheumatologic disorders and cardiovascular disease risk in women. <i>American Heart Journal Plus</i> , 2023, 27, 100267.	0.3	2
736	ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation. <i>Experimental and Molecular Medicine</i> , 2023, 55, 426-442.	3.2	10
737	Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events. <i>CJC Open</i> , 2023, 5, 348-356.	0.7	1
738	Vulnerable Plaque Characteristics at Coronary Computed Tomography Angiography. <i>Cardiologia Croatica</i> , 2023, 18, 7-21.	0.0	1
739	Hyperlipidaemia elicits an atypical, T helper 1â€“like CD4+ T-cell response: a key role for very low-density lipoprotein. <i>European Heart Journal Open</i> , 2023, 3, .	0.9	1
740	Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2023, 45, 101191.	0.6	0
741	Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5155.	1.8	5
742	Coronary artery disease-associated immune gene RBP1 and its pan-cancer analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
743	Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. <i>Journal of Clinical Medicine</i> , 2023, 12, 2161.	1.0	6
744	The diverse roles of macrophages in metabolic inflammation and its resolution. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
745	The Protective Role of TREM2 in the Heterogenous Population of Macrophages during Post-Myocardial Infarction Inflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5556.	1.8	2
746	Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
747	Immunity and inflammation in cardiovascular disorders. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	0.7	5
748	Lipoprotein (a), Inflammation, and Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2529.	1.0	7

#	ARTICLE	IF	CITATIONS
749	Thymidine Phosphorylase Deficiency or Inhibition Preserves Cardiac Function in Mice With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	2
751	Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. <i>Journal of Lipid Research</i> , 2023, 64, 100365.	2.0	1
752	No effect of omega-3 polyunsaturated fatty acid supplementation on inflammatory markers in familial hypercholesterolemia: a randomized crossover trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 152-159.	0.6	0
753	Innate Immunity System in Patients With Cardiovascular and Kidney Disease. <i>Circulation Research</i> , 2023, 132, 915-932.	2.0	8
754	Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110). <i>Rheumatology and Therapy</i> , 2023, 10, 825-847.	1.1	7
755	C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1593-1596.	0.8	4
756	Understanding the molecular mechanisms of statin pleiotropic effects. <i>Archives of Toxicology</i> , 2023, 97, 1529-1545.	1.9	9
760	The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2023, , 307-329.	0.0	0
761	Anti-inflammatory Therapy for Cardiovascular Disease. , 2024, , 224-235.e1.		0
762	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
765	Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. <i>Nature Reviews Rheumatology</i> , 2023, 19, 417-428.	3.5	15
773	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. <i>Contemporary Diabetes</i> , 2023, , 821-878.	0.0	0
778	High-Sensitivity C-Reactive Protein. , 2024, , 69-78.e2.		0
794	A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , 0, , .	1.5	0
818	Inflammation and Vascular Pathologies. <i>Contemporary Endocrinology</i> , 2023, , 147-163.	0.3	0
885	Chronic Inflammation in Atherosclerosis and Arteriosclerosis. , 2024, , 251-260.		0